Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

• DOI: 10.1007/s40487-022-00212-5
• Publication Date: 2022-12-12T12:06:24Z
• Authors: Adrián Alegre; Gonzalo Benzo; Rafael Alonso; Joaquín Martínez-...; Ana Jimenez-Ubieto; Clara Cuéllar; Elham Askari; Elena Prieto; Concepción Aláez; Beatriz Aguado; Alberto Velasco; Isabel Krsnik; Ana Bocanegra; Laura Llorente; Cristina Muñoz-Li...; Ana Morales; Eugenio Giménez; Rebeca Iglesias; Carmen Martínez-C...; Aránzazu Alonso; Carmen Jiménez-Mo...; María J. Blanchard; ; Adrián Alegre; Gonzalo Benzo; Rafael Alonso; Joaquín Martínez-...; Ana Jimenez-Ubieto; Clara Cuéllar; Elham Askari; Elena Prieto; Concepción Aláez; Beatriz Aguado; Alberto Velasco; Isabel Krsnik; Ana Bocanegra; Laura Llorente; Cristina Muñoz-Li...; Ana Morales; Eugenio Giménez; Rebeca Iglesias; Carmen Martínez-C...; Aránzazu Alonso; Carmen Jiménez-Mo...; María J. Blanchard
• Keywords: Refractory (planetary science); Clinical endpoint

Belantamab mafodotin (BM) is a new anti-BCMA antibody-drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP).